Search results for "Fibrosarcoma"

showing 10 items of 35 documents

Atrophic dermatofibrosarcoma protuberans with the fusion gene COL1A1-PDGFB

2008

Fusion geneInfectious DiseasesPDGFBbusiness.industryCancer researchDermatofibrosarcoma protuberansmedicineDermatologymedicine.diseasebusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Urokinase Plasminogen Activator and Gelatinases Are Associated with Membrane Vesicles Shed by Human HT1080 Fibrosarcoma Cells

1997

Membrane vesicles are shed by tumor cells both in vivo and in vitro. Although their functions are not well understood, it has been proposed that they may play multiple roles in tumor progression. We characterized membrane vesicles from human HT1080 fibrosarcoma cell cultures for the presence of proteinases involved in tumor invasion. By gelatin zymography and Western blotting, these vesicles showed major bands corresponding to the zymogen and active forms of gelatinase B (MMP-9) and gelatinase A (MMP-2) and to the MMP-9. tissue inhibitor of metalloproteinase 1 complex. Both gelatinases appeared to be associated with the vesicle membrane. HT1080 cell vesicles also showed a strong, plasminoge…

GelatinasesMacromolecular SubstancesFibrosarcomaBlotting WesternCellGelatinase ABiologyBiochemistryTumor Cells CulturedmedicineHumansCollagenasesFibrinolysinMolecular BiologyGlycoproteinsUrokinaseEnzyme PrecursorsVesicleMetalloendopeptidasesTissue Inhibitor of MetalloproteinasesCell BiologyTissue inhibitor of metalloproteinaseUrokinase-Type Plasminogen ActivatorMolecular biologyExtracellular MatrixUrokinase receptorBloodmedicine.anatomical_structureMatrix Metalloproteinase 9GelatinasesMatrix Metalloproteinase 2HT1080medicine.drugJournal of Biological Chemistry
researchProduct

Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors

2018

Tumors are characterized by leaky blood vessels, and by an abnormal and heterogeneous vascular network. These pathophysiological characteristics contribute to the enhanced permeability and retention (EPR) effect, which is one of the key rationales for developing tumor-targeted drug delivery systems. Vessel abnormality and heterogeneity, however, which typically result from excessive pro-angiogenic signaling, can also hinder efficient drug delivery to and into tumors. Using histidine-rich glycoprotein (HRG) knockout and wild type mice, and HRG-overexpressing and normal t241 fibrosarcoma cells, we evaluated the effect of genetically induced and macrophage-mediated vascular normalization on th…

Histidine-rich glycoproteinUT-Hybrid-DPharmaceutical ScienceVascular normalization02 engineering and technologyPermeabilityArticleMice03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicinePolymethacrylic AcidsCell Line TumorNeoplasmsmedicineAnimalsMethacrylamideTissue DistributionpHPMAFibrosarcomaMice Knockoutchemistry.chemical_classificationDrug CarriersProteins021001 nanoscience & nanotechnologymedicine.diseasePathophysiologyUp-RegulationMice Inbred C57BLHRGNanomedicineTumor targetingchemistryTargeted drug deliveryPermeability (electromagnetism)030220 oncology & carcinogenesisDrug deliveryDrug deliveryCancer researchEPR0210 nano-technologyGlycoprotein
researchProduct

Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells

2011

Lovastatin (Lov), bisphosphonates (BP) and metformin (Met) are widely used drugs, having in common that they interfere with the mevalonate pathway (MP). The MP generates isoprene moieties required for the function of regulatory GTPases controlling cell proliferation and survival. Here, we addressed the question whether MP inhibitors interfere with the anti-tumor efficacy of anticancer drugs. We comparatively analyzed the effect of equitoxic doses of Lov, BP and Met on cell viability, cell cycle progression, apoptosis and DNA damage response (DDR) of human osteo- and fibrosarcoma cells exposed to doxorubicin or cisplatin. We found that Lov, BP and Met modulated the anticancer drug sensitivit…

MAPK/ERK pathwayCancer ResearchDNA damageFibrosarcomaBlotting WesternMevalonic AcidAntineoplastic AgentsApoptosisBone NeoplasmsTumor Cells CulturedmedicineHumansDoxorubicinLovastatinRNA MessengerPhosphorylationCell ProliferationCisplatinOsteosarcomaDiphosphonatesbiologyReverse Transcriptase Polymerase Chain ReactionCell growthCell CycleMetforminOncologyDoxorubicinApoptosisHMG-CoA reductasebiology.proteinCancer researchMevalonate pathwayCisplatinTumor Suppressor Protein p53DNA DamageSignal Transductionmedicine.drugCancer Letters
researchProduct

Incidence and time trends of soft tissue sarcomas in German children 1985-2004 - a report from the population-based German Childhood Cancer Registry.

2008

Abstract The incidence of soft tissue sarcoma (STS) in Europe is increasing, but it is unclear whether this increase can also be seen in Germany. We analysed the heterogeneous group of STS recorded to the German Childhood Cancer Registry (GCCR) between 1985 and 2004 with respect to incidence data. Age-specific, age-standardised and cumulative incidence rates were calculated. Additionally, the average annual percent change (AAPC), derived from a Poisson regression model, was estimated, using time in years as the explanatory, continuous variable. Two thousand sixty-one children were diagnosed at a median age of 72 months. Most common are rhabdomyosarcomas (RMS) (n = 1202) and fibrosarcomas (n…

MaleCancer ResearchPediatricsmedicine.medical_specialtyTime FactorsFibrosarcomasymbols.namesakeAge DistributionGermanyEpidemiologyRhabdomyosarcomaMedicineHumansCumulative incidencePoisson regressionChildChildhood Cancer Registrybusiness.industryIncidence (epidemiology)Soft tissue sarcomaSarcomamedicine.diseaseAnnual Percent ChangeCancer registryOncologyChild PreschoolsymbolsFemalebusinessEpidemiologic MethodsEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Biphasic dermatofibrosarcoma protuberans with a labyrinthine plexiform high‐grade fibrosarcomatous transformation

2013

Several variants of dermatofibrosarcoma protuberans, a low-grade superficial sarcoma, are well recognized. The most prognostically important is the fibrosarcomatous variant. We report a case of biphasic dermatofibrosarcoma protuberans in which the high-grade component exhibited a previously undescribed plexiform pattern. A clinicopathological study complemented with immunohistochemical, ultrastructural, reverse transcription polymerase chain reaction and fluorescence in situ hybridization analyses of this unique case. Histopathologically, a conventional low-grade dermatofibrosarcoma protuberans was admixed with intratumoral high-grade areas showing a striking labyrinthine plexiform pattern …

MalePathologymedicine.medical_specialtySkin NeoplasmsHistologyOncogene Proteins FusionFibrosarcomaCD34DermatologyBiologyPathology and Forensic MedicinemedicineDermatofibrosarcoma protuberansHumansIn Situ Hybridization FluorescencePDGFBmedicine.diagnostic_testDermatofibrosarcomaMiddle AgedPrognosismedicine.diseaseImmunohistochemistryCell Transformation NeoplasticCOL1A1/PDGFB Fusion GeneImmunohistochemistrySarcomaImmunostainingFluorescence in situ hybridizationJournal of Cutaneous Pathology
researchProduct

Fibrosarcoma in pediatric patients: Results of the Italian Cooperative Group Studies (1979-1995)

2001

Background and Objectives Fibrosarcoma is a rare soft tissue sarcoma (STS) that has two peaks of incidence in pediatric patients: one in infants and young childern (infantile fibrosarcoma), another in older children (“adult type” fibrosarcoma). The purpose of this study was to describe the clinical features and the treatment results in patients affected by fibrosarcoma enrolled in two consecutive studies run by the STS-Italian Cooperative Group (ICG) between 1979 and 1995. Patients and Methods Twenty-five evaluable patients were grouped according the intergroup rhabdomyosarcoma staging (IRS) system: 12 Gr I, 5 Gr II, 8 Gr III. The cut-off point between the two forms was considered the age o…

Malemedicine.medical_specialtyinfantile fibrosarcomaAdolescentmedicine.medical_treatmentSoft Tissue NeoplasmsSettore MED/38 - Pediatria Generale E SpecialisticamedicineHumansFibrosarcomaRhabdomyosarcomaChildSurvival analysisfibrosarcoma; infantile fibrosarcoma; soft tissue sarcomabusiness.industrySoft tissue sarcomaSettore MED/20 - Chirurgia Pediatrica E InfantileAge FactorsInfantRadiotherapy DosageSarcomaGeneral Medicinemedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschoolsoft tissue sarcomaSurgeryFemalefibrosarcomaSarcomaInfantile FibrosarcomabusinessProgressive disease
researchProduct

Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells

2012

The multidrug resistance-associated protein 2 (MRP2/ABCC2) is involved in the efflux of endogenous and xenobiotic substrates, including several anticancer and antiviral drugs. The functional consequences of ABCC2 protein variants remain inconsistent, which may be due to shortcomings of the in vitro assays used. To study systematically the functional consequences of nonsynonymous ABCC2 variants, we used a novel “Screen and Insert” (ScIn) technology to achieve stable and highly reproducible expression of 13 ABCC2 variants in HT1080 cells. Western blotting revealed lower (30–65%) ABCC2 expression for D333G, R1174H, and R1181L as compared with wild type (WT; 100%), whereas the linked variant V1…

Nonsynonymous substitutionFibrosarcomaMutation MissenseATP-binding cassette transporterBiologyCell Line TumorGeneticsHumansGenetics (clinical)GeneticsAsianMultidrug resistance-associated protein 2Endoplasmic reticulumChloraminesWild typeGenetic VariationTetracyclineMolecular biologyMultidrug Resistance-Associated Protein 2Recombinant ProteinsBlack or African AmericanBlotHEK293 CellsGene Expression RegulationHaplotypesHT1080EffluxMultidrug Resistance-Associated ProteinsHuman Mutation
researchProduct

Reply to "More evidence that genetic profiling will delineate the nosology and biologic potential of fibrohistiocytic tumors in the dermatofibrosarco…

2013

NosologyMalemedicine.medical_specialtyPathologySkin NeoplasmsOncogene Proteins Fusionbusiness.industryDermatofibrosarcomaDermatologymedicine.diseaseDermatologyDermatofibrosarcoma protuberansMedicineHumansFemalebusinessJournal of the American Academy of Dermatology
researchProduct

FU-3 monoclonal antibody: a specific marker for malignant fibrous histiocytoma? An analysis of 32 malignant soft tissue and bone sarcomas.

1994

An immunohistochemical study on frozen sections was carried out on 51 malignant tumours of soft tissue and bone using the FU-3 monoclonal antibody. This antibody is claimed to be specific for malignant fibrous histiocytoma (MFH) and liposarcoma and for normal and tumour cells located in perivascular fields. The results show a lack of specificity in MFH staining: several malignant tumours such as synovial sarcoma, fibrosarcoma, rhabdomyosarcoma, osteogenic sarcoma, and including an anaplastic malignant melanoma, presented positive staining somewhat similar to that found in MFH. The value of this antibody in the differential diagnosis of MFH is doubtful. It might be useful to recognize a comm…

Pathologymedicine.medical_specialtyHistiocytoma Benign Fibrousbusiness.industrySoft tissueAntibodies MonoclonalBone NeoplasmsSarcomaCell BiologyGeneral MedicineBone SarcomaLiposarcomamedicine.diseaseImmunohistochemistrySynovial sarcomaPathology and Forensic MedicinemedicineImmunohistochemistryHumansSarcomaFibrosarcomabusinessRhabdomyosarcomaMolecular BiologyVirchows Archiv : an international journal of pathology
researchProduct